Trial Profile
Safety, Preliminary Pharmacokinetics and Bronchodilator Properties of V0162.
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 08 Apr 2020
Price :
$35
*
At a glance
- Drugs V 0162 (Primary)
- Indications Chronic obstructive pulmonary disease
- Focus Adverse reactions
- Sponsors Pierre Fabre
- 01 Jul 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 07 May 2011 New trial record